Odds
Yes91%
Market details
Status
void
Positions
3
Volume
170 cr
Locks
Jan 23, 2026
Updated
Dec 22, 2025, 07:43 AM
Rules summary
Resolves YES if Wegovy (semaglutide) US WAC annualized price is < $12,000/year as of Dec 31, 2026. Primary source: sponsor WAC list price publication or a clearly cited WAC source. Otherwise NO.
Market context
High-interest obesity market; keep resolution strict and source-driven.
People are also buying
BrowseCommunity vote50% Yes · 0 votes
VoteVoting closed